Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection

计划入组 124 人 · 首次发布于 2019 年 4 月 16 日

Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73

计划入组 48 人 · 首次发布于 2012 年 5 月 7 日

Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects

计划入组 60 人 · 首次发布于 2014 年 11 月 4 日

XF-70

XF-42

CPT-1

DERMAL LABORATORIES LIMITED

United Kingdom

Dermal Laboratories Ltd.

United Kingdom

AEROPAK (CHEMICAL PRODUCTS) LIMITED

United Kingdom

AMR Bio Launches with Phase III-Ready Antimicrobial XF-73 to Combat Post-Surgical Infections

Evolus Submits FDA Application for Evolysse Sculpt Mid-Face Dermal Filler

FDA Approves Evolus' Novel Hyaluronic Acid Dermal Fillers with Superior Efficacy Profile